 |
Case Report
Follicular spiny hyperkeratosis induced by sorafenib
1 Department of Dermatology, General Hospital “Dr. Manuel Gea González” Ciudad de México, Mexico City, Mexico
2 Department of Dermatopathology, General Hospital “Dr. Manuel Gea González” Ciudad de México, Mexico City, Mexico
Address correspondence to:
Marianne Thérèse Signoret-Bravo
MD, General Hospital “Dr. Manuel Gea González”, Calzada de Tlalpan 4800, Section XVI, Tlalpan, CP 14080, Mexico City,
Mexico
Message to Corresponding Author
Article ID: 100141Z10MB2025
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Signoret-Bravo MT, Briseño-Gascon G, Figueroa-Hernández MF, Berumen-Glinz C, Toussaint-Caire S, Vega-Memije ME. Follicular spiny hyperkeratosis induced by sorafenib. J Case Rep Images Oncology 2025;11(1):5–8.ABSTRACT
Introduction: Follicular spiny hyperkeratosis is a rare dermatosis, usually related to multiple myeloma. Some cases associated with drug use have been reported.
Case Report: A 60-year-old male patient with a history of papillary thyroid cancer started treatment with sorafenib. Ten days later, he presented with a dermatosis affecting the scalp and forehead, characterized by thick interfollicular scaling and spiny hyperkeratosis. Dermoscopy revealed tubular scaling along the hair shaft. A skin biopsy was performed, revealing a spine of compact parakeratotic material, leading to the diagnosis of follicular spiny hyperkeratosis.
Conclusion: Follicular spiny hyperkeratosis can develop after exposure to sorafenib. Recognizing it allows for timely identification of causality and optimal individualized management.
Keywords: Follicular spicules, Follicular spiny hyperkeratosis, Sorafenib, Tyrosine-kinase inhibitors
SUPPORTING INFORMATION
Author Contributions
Marianne Thérèse Signoret-Bravo - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Genaro Briseño-Gascon - Substantial contributions to conception and design, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Maria Fernanda Figueroa-Hernández - Interpretation of data, Drafting the article, Final approval of the version to be published
Cristina Berumen-Glinz - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Sonia Toussaint-Caire - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
María Elisa Vega-Memije - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2025 Marianne Thérèse Signoret-Bravo et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
